In this work, we report the redox properties in organic catalytic transformation and antibacterial activity of novel Cu Ag Zn O nanocomposites. Cu- and Ag-doped ZnO [Cu Ag Zn O ( = 0.1)] (CAZ), Cu-doped ZnO [Cu Zn O ( = 0.1)] (CZ), and Ag-doped ZnO [Ag Zn O ( = 0.1)] (AZ) were prepared via a chemical co-precipitation method. The synthesized nanocomposites were characterized using different spectroscopic techniques. The catalytic activity of CAZ, CZ, and AZ was examined for the reduction of 4-nitrophenol (4-NP) and 4-nitroaniline (4-NA) in the presence of NaBH in an aqueous medium. The photocatalytic oxidation efficiency of these catalysts was also observed against naphthol orange (NO) under ultraviolet light. It was found that the catalytic reduction and oxidation efficiency of CAZ is higher than that of CZ and AZ in 4-NP/4-NA and NO in a water solvent, respectively. The antibacterial property of CAZ was also studied against Gram-positive and Gram-negative bacteria by agar well diffusion and the minimum inhibitory concentration methods. It was found that CAZ shows better antimicrobial activity compared to its parental Cu(NO)·3HO, AgNO, and ZnO. Therefore, the incorporation of Cu and Ag into ZnO increases its catalytic and antimicrobial activity remarkably. Fourier-transform infrared and X-ray diffraction (XRD) studies of CAZ indicate the incorporation of Cu and Ag into the lattice of ZnO. The phase structure of CAZ was wurtzite hexagonal, and the average crystallite size was 93 ± 1 nm measured from XRD. The average grain size and particle size of CAZ were found to be 200 and 100 ± 5 nm originating from SEM and transmission electron microscopy studies, respectively. The optical energy band gap of CAZ is 3.15 eV, which supports the excellent photocatalyst under UV light. CAZ also exhibits good agreement for photoluminescence properties with a high intensity peak at 571 nm, indicating surface oxygen vacancies and defects which might be responsible for higher photocatalytic activity compared to others. The nanocomposite shows excellent reusability without any significant loss of activity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582044PMC
http://dx.doi.org/10.1021/acsomega.1c03925DOI Listing

Publication Analysis

Top Keywords

caz
10
aqueous medium
8
antibacterial activity
8
activity novel
8
novel nanocomposites
8
ag-doped zno
8
zno [cu
8
[cu 01]
8
oxidation efficiency
8
antimicrobial activity
8

Similar Publications

Objectives: To evaluate the rationality of the clinical use of ceftazidime-avibactam (CAZ-AVI) for carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in a real-world setting.

Methods: We established the rational evaluation criteria based on drug instructions and relevant guidelines to retrospectively evaluate the use of CAZ-AVI to treat CRKP infections from June 2020 to June 2023 in a tertiary hospital in China. Patients were divided into the rational use group and irrational use group.

View Article and Find Full Text PDF

Background And Aim: Comparative studies of Ceftazidime/avibactam(CAZ/AVI) versus polymyxin B (PMB) for carbapenem-resistant organisms (CRO) infections are limited. We aims to compare the efficacy and safety of CAZ/AVI and PMB in treating CRO infections.

Methods: This single-center, propensity score-matched (PSM) retrospective cohort study involved adult patients with CRO infections.

View Article and Find Full Text PDF

Sub-minimum inhibitory concentrations in ceftazidime exacerbate the formation of Acinetobacter baumannii biofilms.

Microb Pathog

December 2024

Laboratory of Applied Microbiology and Cancer Remedies, School of Life Sciences, Jawaharlal Nehru University, New Delhi, 110067, India. Electronic address:

Associated with nosocomial infections, the environmental Gram-negative coccobacillus A. baumannii leads to various kinds of high mortality-rate infections among which pneumonias mainly in immune-compromised people from health-care facilities. A critical component of the current antibiotic resistance problem is the presence of antibiotics sub-minimum inhibitory concentrations (sub-MICs) in a variety of natural settings including drinking water, sewage water, rivers, lakes, and natural sludge.

View Article and Find Full Text PDF

Tazobactam/ceftolozane (TAZ/CTLZ) and relebactam/imipenem/cilastatin (REL/IPM/CS) are expected to be effective for treating patients with antimicrobial-resistant infections, particularly gram-negative pathogens, but nationwide surveillance of these has not been investigated thoroughly in Japan. Pseudomonas aeruginosa (n=164), Klebsiella pneumoniae (n=141), and Haemophilus influenzae (n=156) isolated from respiratory infected patients in Japan from June 2019 through December 2020 provided by the Japanese Surveillance Committee were used. Antimicrobial susceptibility testing for TAZ/CTLZ, REL/IPM and comparator agents against isolates were carried out by broth microdilution methods according to the Clinical and Laboratory Standards Institute standard.

View Article and Find Full Text PDF
Article Synopsis
  • Major depressive disorder (MDD) includes a challenging subset known as treatment-resistant depression (TRD), which can be effectively targeted using rapid-acting antidepressants such as ketamine and esketamine, though individual responses vary.
  • Research is focusing on identifying clinical predictors for better treatment outcomes with ketamine/esketamine, including factors like family history of alcohol use and history of childhood trauma, as well as potential brain-based biomarkers detected through EEG.
  • Most response predictors show modest effects, thus future studies should employ multivariate models and standardize biomarker collection methods to improve the robustness and comparability of findings across trials.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!